No Data
No Data
Are Investors Undervaluing Xiamen Amoytop Biotech Co., Ltd. (SHSE:688278) By 47%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Xiamen Amoytop Biotech fair value estimate is CN¥112 Current share price of CN¥59.50 suggests Xiamen Amoytop Biotech is potentially 47% under
Tebao Biotech (688278.SH): Net profit of 129 million yuan in the first quarter increased 53.03% year-on-year
Gelonghui, April 22丨Tebao Biotech (688278.SH) released its report for the first quarter of 2024. Operating revenue for the reporting period was 545 million yuan, up 30.05% year on year; net profit attributable to shareholders of listed companies was 129 million yuan, up 53.03% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 146 million yuan, up 42.90% year on year; basic earnings per share were 0.32 yuan.
Tebao Biotech (688278.SH): Approved as a high-tech enterprise
Gelonghui, April 15, 丨 Tebao Biotech (688278.SH) announced that the company recently received the “High-tech Enterprise Certificate” (certificate number: GR202335100220) jointly issued by the Xiamen Municipal Bureau of Science and Technology, the Xiamen Municipal Finance Bureau, and the Xiamen Municipal Taxation Bureau of the State Administration of Taxation. The issuance period is November 22, 2023, and the certificate is valid for three years. This high-tech enterprise certification is a re-certification carried out after the expiration of the company's original certificate.
There May Be Underlying Issues With The Quality Of Xiamen Amoytop Biotech's (SHSE:688278) Earnings
Last week's profit announcement from Xiamen Amoytop Biotech Co., Ltd. (SHSE:688278) was underwhelming for investors, despite headline numbers being robust. Our analysis uncovered some concerning fact
Guojin Securities's April industry allocation: gradually shifting from a “small to medium market growth attack” to a “large market value defense” (with April's top ten gold stocks)
Although the current risks have not been clearly revealed, they are gradually accumulating, and the “cost performance ratio” of investment returns is declining. It is expected that the upward momentum of A-shares in April will probably weaken.
China Stocks Advance Over Positive Economic Data; Amoytop Biotech Rises 6%
Chinese shares advanced on the first day of the trading week as sentiment turned upbeat over positive economic indicators reported on Monday, with retail sales and industrial output both surpassing ex
No Data